Ocular Therapeutix Inc. (NASDAQ:OCUL) saw a downside of -2.55% to close Friday at $4.20 after subtracting -$0.11 on the day. The 5-day average trading volume is 858,400 shares of the company’s common stock. It has gained $4.56 in the past week and touched a new high 3 times within the past 5 days. An average of 835,185 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,226,142.
OCUL’s 1-month performance is -6.87% or -$0.29 on its low of $3.66 reached on 08/08/23. The company’s shares have touched a 52-week low of $2.57 and high of $7.96, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, OCUL has achieved 49.47% or $1.39 and has reached a new high 18 times. However, the current price is down -47.24% from the 52-week high price.
Insider Transactions
OCUL stock investors last saw insider trading activity on Jul 07.Ozden Rabia Gurses (Chief Medical Officer) most recently sold 832 shares at $4.93 per share on Jul 07. This transaction cost the insider $4,102. President and CEO, Mattessich Antony C., sold 19,669 shares at a price of $4.24 on Feb 06. Then, on Feb 06, Chief Financial Officer Notman Donald sold 6,476 shares at a price of $4.24 per share. This transaction amounted to $27,458.
Valuation Metrics
OCUL stock has a beta of 1.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.27 while the price-to-book (PB) in the most recent quarter is 105.00.
Ocular Therapeutix Inc.’s quick ratio for the period ended June 30 was 3.00, with the current ratio over the same period at 3.10. As well, the company’s long term debt to equity for the quarter ending June 30 was 17.19, while the total debt to equity was 17.87. In terms of profitability, the gross margin trailing 12 months is 91.60%. The firm’s gross profit as reported stood at $46.95 million against revenue of $51.49 million.
Earnings Surprise
For the quarterly period ending June 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 9.24% to -$20.68 million, while revenue of -$30.32 million was -46.62% off the previous quarter. Analysts expected OCUL to announce -$0.3 per share in earnings in its latest quarter, but it posted -$0.26, representing a 13.30% surprise. EBITDA for the quarter stood at more than -$19.92 million. OCUL stock balance sheet for the quarter ending June 30 shows that total liabilities totaled 119.47 million, with total debt at $64.77 million. Shareholders hold equity totaling $79.39 million.
Let’s look briefly at Ocular Therapeutix Inc. (OCUL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 43.01% to suggest the stock is trending Neutral, with historical volatility in this time period at 87.31%.
The stock’s 5-day moving average is $4.38, reflecting a -3.45% or -$0.15 change from its current price. OCUL is currently trading -8.30% above its 20-day SMA, -18.29% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -43.32% and SMA200 by+16.34%.
Stochastic %K and %D was 69.55% and 78.21% and the average true range (ATR) pointed at 0.25. The RSI (14) points at 42.53%, while the 14-day stochastic is at 60.00% with the period’s ATR at 0.26. The stock’s 9-day MACD Oscillator is pointing at 0.09 and 0.02 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Ocular Therapeutix Inc. (NASDAQ: OCUL), Robert W. Baird launched coverage with an Outperform rating.
